Bioidentical hormone replacement therapy (BHRT) uses hormones that are identical to the body’s endogenous hormones to replenish what the body cannot produce.
Conventional (synthetic) hormones do not structurally match the hormones produced by the human body. Conventional hormones contain tiny molecular differences that causes the body to recognizes them as foreign substances. For this reason, synthetic estrogen-replacement drugs increase the risk of several potentially fatal diseases, especially when combined with progestin, the synthetic form of progesterone.
In 2002, a large-scale study known as the Women’s Health Initiative (WHI) revealed that postmenopausal women who used a combination of synthetic estrogen and progestin had a higher risk of breast cancer, coronary artery disease, stroke, and blood clots. In response to this alarming news, many doctors immediately recommended that patients stop synthetic HRT. The following year, statistics revealed that breast cancer rates overall dropped about 7 percent and estrogen-sensitive breast cancers (which are more likely to occur when estrogen levels are high) among women ages 50-69 fell 12-percent.
Bioidentical hormones can be produced to replace any of the several types of hormones deficiencies and can be individualized for the needs of your patients. The various delivery methods available for BHRT include intra-dermal patches, foam, creams, oral, sublingual troches, and implantable pellets. Therefore the dosing can be individualized to the patient and can be delivered in a readily absorbable and gradual rate. There are very few side effects associated with these hormones as compared to pharmaceutical synthetic hormones and can flow easily through the steroid pathway and interact seamlessly to produce balancing of these hormones through supplementation.